Posted by Michael Wonder on 11 Apr 2024
Fasenra approved for treatment of children aged 6 to 11 with severe asthma
11 April 2024 - AstraZeneca’s Fasenra (benralizumab) is now approved by the US FDA for add-on maintenance treatment for patients with severe asthma aged 6 to 11 with an eosinophilic phenotype.
This additional indication for Fasenra was supported by evidence from TATE, an open-label, multinational, non-randomised, parallel assignment Phase 3 trial, as well as adequate and well-controlled trials in adult and adolescent populations.
